ES2214608T3 - Moleculas hidrofobas receptoras de sustancias antigenas y que comprenden complejos inmunoestimulantes o matrices complejas inmunoestimulantes. - Google Patents
Moleculas hidrofobas receptoras de sustancias antigenas y que comprenden complejos inmunoestimulantes o matrices complejas inmunoestimulantes.Info
- Publication number
- ES2214608T3 ES2214608T3 ES97905539T ES97905539T ES2214608T3 ES 2214608 T3 ES2214608 T3 ES 2214608T3 ES 97905539 T ES97905539 T ES 97905539T ES 97905539 T ES97905539 T ES 97905539T ES 2214608 T3 ES2214608 T3 ES 2214608T3
- Authority
- ES
- Spain
- Prior art keywords
- rctb
- antigen
- lipid
- matrix
- iscom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Nanotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600648A SE9600648D0 (sv) | 1996-02-21 | 1996-02-21 | Receptorbimdande enhet |
| SE9600648 | 1996-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2214608T3 true ES2214608T3 (es) | 2004-09-16 |
Family
ID=20401482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97905539T Expired - Lifetime ES2214608T3 (es) | 1996-02-21 | 1997-02-20 | Moleculas hidrofobas receptoras de sustancias antigenas y que comprenden complejos inmunoestimulantes o matrices complejas inmunoestimulantes. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6027732A (de) |
| EP (1) | EP0944397B1 (de) |
| AT (1) | ATE258066T1 (de) |
| AU (1) | AU718443B2 (de) |
| BR (1) | BR9707638A (de) |
| CA (1) | CA2247103C (de) |
| DE (1) | DE69727314T2 (de) |
| DK (1) | DK0944397T3 (de) |
| ES (1) | ES2214608T3 (de) |
| NZ (1) | NZ331418A (de) |
| SE (1) | SE9600648D0 (de) |
| WO (1) | WO1997030726A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| DE60044236D1 (de) * | 1999-02-17 | 2010-06-02 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
| DE60039715D1 (de) * | 1999-11-19 | 2008-09-11 | Csl Ltd | Hcv-impfstoff zusammensetzungen |
| SE0003538D0 (sv) * | 2000-09-29 | 2000-09-29 | Isconova Ab | New immunogenic complex |
| US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| US20030138434A1 (en) * | 2001-08-13 | 2003-07-24 | Campbell Robert L. | Agents for enhancing the immune response |
| ATE361097T1 (de) * | 2002-01-15 | 2007-05-15 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Orale vakzinierung mit dem tumor-antigen-mimotop gln-met-trp-ala-pro-gln-trp-gly-pro-asp |
| EP1608403A2 (de) * | 2003-04-02 | 2005-12-28 | Coley Pharmaceutical Group, Ltd. | Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung |
| US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
| JP2008506789A (ja) * | 2004-07-18 | 2008-03-06 | シーエスエル、リミテッド | インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物 |
| EP2468300B1 (de) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Impfstoffzusammensetzung mit einem synthetischen Adjuvans |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| ES2325243B1 (es) * | 2008-02-27 | 2011-05-04 | Universidad De Granada | Antigeno recombinante. |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| PL2811981T3 (pl) | 2012-02-07 | 2019-09-30 | Infectious Disease Research Institute | Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania |
| SMT201800368T1 (it) | 2012-05-16 | 2018-09-13 | Immune Design Corp | Vaccini per l'infezione da virus-2 herpes simplex |
| CA2909221A1 (en) | 2013-04-18 | 2014-10-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| IL310015B2 (en) | 2013-12-31 | 2026-02-01 | Access To Advanced Health Inst | Single vial formulation |
| BR112021023726A2 (pt) | 2019-05-25 | 2022-02-15 | Infectious Disease Res Inst | Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante |
| EP4058581A1 (de) | 2019-11-15 | 2022-09-21 | Infectious Disease Research Institute | Rig-i-agonist und adjuvans-formulierung zur tumorbehandlung |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2403081A1 (fr) * | 1977-09-19 | 1979-04-13 | Merieux Inst | Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament |
| US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
-
1996
- 1996-02-21 SE SE9600648A patent/SE9600648D0/xx unknown
-
1997
- 1997-02-20 EP EP97905539A patent/EP0944397B1/de not_active Expired - Lifetime
- 1997-02-20 DE DE1997627314 patent/DE69727314T2/de not_active Expired - Lifetime
- 1997-02-20 AU AU22383/97A patent/AU718443B2/en not_active Expired
- 1997-02-20 ES ES97905539T patent/ES2214608T3/es not_active Expired - Lifetime
- 1997-02-20 WO PCT/SE1997/000287 patent/WO1997030726A1/en not_active Ceased
- 1997-02-20 NZ NZ331418A patent/NZ331418A/xx not_active IP Right Cessation
- 1997-02-20 BR BR9707638-4A patent/BR9707638A/pt not_active IP Right Cessation
- 1997-02-20 DK DK97905539T patent/DK0944397T3/da active
- 1997-02-20 CA CA002247103A patent/CA2247103C/en not_active Expired - Fee Related
- 1997-02-20 US US09/125,588 patent/US6027732A/en not_active Expired - Lifetime
- 1997-02-20 AT AT97905539T patent/ATE258066T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0944397B1 (de) | 2004-01-21 |
| CA2247103A1 (en) | 1997-08-28 |
| NZ331418A (en) | 2000-03-27 |
| US6027732A (en) | 2000-02-22 |
| CA2247103C (en) | 2009-01-20 |
| ATE258066T1 (de) | 2004-02-15 |
| AU2238397A (en) | 1997-09-10 |
| BR9707638A (pt) | 2000-01-04 |
| EP0944397A1 (de) | 1999-09-29 |
| SE9600648D0 (sv) | 1996-02-21 |
| DK0944397T3 (da) | 2004-06-01 |
| WO1997030726A1 (en) | 1997-08-28 |
| AU718443B2 (en) | 2000-04-13 |
| DE69727314D1 (de) | 2004-02-26 |
| DE69727314T2 (de) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0944397B1 (de) | Ein hydrophobes rezeptormolekül für antigene stoffen enthaltender immunstimulierender komplex (iscom) oder matrix gebundener immunstimulierender komplex (iscom-matrix) | |
| EP0889736B1 (de) | Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält | |
| ES2593862T3 (es) | Métodos y composiciones de formulación liposomal de antígenos y usos de los mismos | |
| ES2198089T3 (es) | Vacunas con un adyuvante constituido por ltb. | |
| CN103747797B (zh) | 脂质体制剂 | |
| JP4535211B2 (ja) | コクリエート送達ビヒクル | |
| CA2086831C (en) | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them | |
| ES2283070T3 (es) | Utilizacion de oligonucleotidos inmunoestimulantes para la prevencion o tratamiento del asma. | |
| ES2296629T3 (es) | Composiciones adyuvantes inmunologicas acuosas de monofosforil-lipido a. | |
| EP0773786B1 (de) | Quinoa saponin zubereitungen und verfahren zur verwendung | |
| US10456459B2 (en) | Liposomal adjuvant compositions | |
| FR2732605A1 (fr) | Composition destinee a l'induction d'une reponse immunitaire mucosale | |
| CN102123724A (zh) | 治疗流行性感冒的组合物和方法 | |
| ES2433467T3 (es) | Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina | |
| Rask et al. | Mucosal and systemic antibody responses after peroral or intranasal immunization: Effects of conjugation to enterotoxin B subunits and/or of co‐administration with free toxin as adjuvant | |
| ES2285466T3 (es) | Combinaciones adyuvantes de liposomas y lipidos de micobacterias para composiciones de inmunizacion y vacunas. | |
| CN107847603B (zh) | 脂质体佐剂组合物 | |
| JPH08337598A (ja) | 非型性のヘモフイルス インフルエンザ（Ｈａｅｍｏｐｈｉｌｕｓ ｉｎｆｌｕｅｎｚａｅ）株用のワクチンとしての精製非型性ヘモフイルス インフルエンザＰ５蛋白質 | |
| WO2013091260A1 (zh) | 龋齿疫苗及制备方法 | |
| JP2002521460A (ja) | 肺サーファクタントを含むアジュバント | |
| US20250170236A1 (en) | A novel cationic adjuvant composition | |
| ES2234152T3 (es) | Vectores de antigenos en forma de vesiculas multilamelares. | |
| JPH06503555A (ja) | ワクチン | |
| US20240082421A1 (en) | Composition for immune tolerance induction and use in gene therapy | |
| ES2358900T3 (es) | Composiciones que comprenden complejos de antígenos, procedimiento para su preparación así como precedimientos de utilización de los complejos de antígenos para la vacunación. |